Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42
Authors:
- Seong Soo A. AnSeong Soo A. An
- Byoung-Sub LeeBLByoung-Sub Lee
- Ji Sun YuJYJi Sun Yu
- Kuntaek LimKLKuntaek Lim
- Gwang Je KimGKGwang Je Kim
- Ryan LeeRLRyan Lee
- Shinwon KimSKShinwon Kim
- Sungmin KangSKSungmin Kang
- Young Ho ParkYPYoung Ho Park
- Min Jeong WangMWMin Jeong Wang
- Young Soon YangYYYoung Soon Yang
- Young Chul YounYYYoung Chul Youn
Open Access
- 17 October 2017
- journal article
- research article
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 9 (1) , 1-10
Abstract
A reliable blood-based assay is required to properly diagnose and monitor Alzheimer’s disease (AD). Many attempts have been made to develop such a diagnostic tool by measuring amyloid-β oligomers (AβOs) in the blood, but none have been successful in terms of method reliability. We present a multimer detection system (MDS), initially developed for the detection of prion oligomers in the blood, to detect AβOs. To characterize Aβ in the blood, plasma was spiked with synthetic amyloid-β (Aβ) and incubated over time. Then, the MDS was used to monitor the dynamic changes of AβO levels in the plasma. Increasing concentrations of AβOs were observed in the plasma of patients with AD but not in the plasma of normal control subjects. The plasma from patients with AD (n = 27) was differentiated from that of the age-matched normal control subjects (n = 144) with a sensitivity of 83.3% and a specificity of 90.0%. Synthetic Aβ spiked into the blood plasma of patients with AD, but that of not elderly normal control subjects, induced dynamic changes in the formation of AβOs over time. AβOs were detected by the MDS, which is a useful blood-based assay with high sensitivity and specificity for AD diagnosis.Keywords
Funding Information
- Korea Health Industry Development Institute (HI14C3331)
- National Research Foundation of Korea (2017R1A2B4012636)
This publication has 48 references indexed in Scilit:
- Neurotoxic amyloid beta oligomeric assemblies recreated in microfluidic platform with interstitial level of slow flowScientific Reports, 2013
- Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's DiseasePLOS ONE, 2012
- Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementiaTrends in Neurosciences, 2011
- Aβ42 Neurotoxicity Is Mediated by Ongoing Nucleated Polymerization Process Rather than by Discrete Aβ42 SpeciesJournal of Biological Chemistry, 2011
- Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot studyBMC Neurology, 2010
- Molecular mechanism of Thioflavin-T binding to amyloid fibrilsBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2010
- Biological markers of amyloid β-related mechanisms in Alzheimer's diseaseExperimental Neurology, 2010
- A Specific Enzyme-Linked Immunosorbent Assay for Measuring β-Amyloid Protein Oligomers in Human Plasma and Brain Tissue of Patients With Alzheimer DiseaseArchives of Neurology, 2009
- Oligomers of the amyloid-β protein disrupt working memory: Confirmation with two behavioral proceduresBehavioural Brain Research, 2008
- Natural oligomers of the amyloid-β protein specifically disrupt cognitive functionNature Neuroscience, 2004